Role of Mitochondria in Non Severe Asthma (MITASTHME)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Asthma is a frequent disease characterized by bronchial hyperresponsiveness, inflammation and remodelling. Bronchial remodelling is an abnormal repair process that contributes to the development of poorly reversible airway narrowing. It can appear very early in the evolution of the disease and involves an increased mass of bronchial smooth muscle (BSM). The mechanism of such an increase has been related with an increase in smooth muscle cell proliferation. Recently, we have demonstrated that, BSM increased proliferation is induced by an enhanced mitochondrial biogenesis in severe asthma (T. Trian et al. J Exp Med 2007). The objective of this study is to investigate the role of smooth muscle cell mitochondria in non severe asthma
| Condition | Intervention |
|---|---|
|
Asthma |
Procedure: fiberoptic fibroscopy |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Health Services Research |
| Official Title: | Role of Mitochondria in Human Bronchial Smooth Muscle Remodeling in Non Severe Asthma |
- BSM mitochondrial biogenesis assessed by the number of mitochondrial sections using electron microscopy, the porin content using western blot, and mitochondrial oxygen consumption evaluated by oxygraphy. [ Time Frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment ] [ Designated as safety issue: No ]
- BSM remodelling assessed by optic microscopy and immunohistochemistry (using anti-alpha smooth muscle actin antibody). [ Time Frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment ] [ Designated as safety issue: No ]
- Transcription factors involved in mitochondrial biogenesis assessed by quantitative RT-PCR and western blot. [ Time Frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment ] [ Designated as safety issue: No ]
| Enrollment: | 32 |
| Study Start Date: | February 2009 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
fiberoptic fibroscopy
|
Procedure: fiberoptic fibroscopy
Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
|
Detailed Description:
Bronchial remodelling mainly involves an increased mass of bronchial smooth muscle (BSM), which is related with an increase proliferation of BSM cells. Recently, using BSM cells obtained from severe asthmatics, we have demonstrated that such an increase proliferation was induced by an activation cascade involving an abnormal calcium entry, and the subsequent activation of Calmodulin-kinase IV, PGC-1alpha, NRF-1 and mt-TFA leading to an increase mitochondrial biogenesis (T. Trian et al, J Exp Med 2007). The objective of this study is to investigate the role of BSM cell mitochondria in non severe asthma.
For this purpose, 30 non severe asthmatic adult patients (>18 yr) will be prospectively recruited from the "CHU de Bordeaux" according to the Global Initiative for Asthma (GINA) guidelines. Inclusion visit will include written informed consent, asthma control questionnaire, clinical examination, lung function testing (i.e. arterial gas, exhaled NO, plethysmography), prick tests, chest X Ray and blood sample for total IgE levels. Bronchial specimens will be obtained from all subjects by fiberoptic bronchoscopy. BSM remodelling will be evaluated by morphological analysis. Patients will be divided into 2 groups according to the presence or the absence of BSM remodelling. Using BSM cell culture, the role of mitochondria will be analyzed by electronic microscopy, confocal microscopy, immunoblotting, RT-PCR and oxygraphy.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female aged more than 18 years
- Diagnosis of intermittent asthma, mild persistent asthma or moderate persistent according to ATS criteria
- Forced expiratory volume in one second > 60% predicted
- Written informed consent
Exclusion Criteria:
- Smoker or former smoker (tobacco or cannabis)
- Adults protected by law
- Subjects not affiliated with social security
- Subjects during exclusion relative to another protocol or for which the annual maximum allowance of 3800 euros has been reached
- Subject with any co-morbidity (except chronic rhinitis, chronic sinusitis nasal polyps or gastro-oesophageal reflux)
- Asthma exacerbation within 6 weeks before enrolment
- Infections of the upper airway within 3 months before enrolment
- Chronic viral infections (hepatitis, HIV)
- Pregnancy or breastfeeding
- Contraindications to bronchoscopy
Contacts and Locations| France | |
| University Hospital Bordeaux, Hôpital Haut-Lévêque | |
| Pessac, France, 33604 | |
| Principal Investigator: | Pierre-Olivier GIRODET, MCU-PH | University Hospital Bordeaux / Département de Pharmacologie, CIC - Université Victor Segalen Bordeaux 2 |
More Information
Publications:
| Responsible Party: | Jean-Pierre LEROY / Clinical Research and Innovation Director, University Hospital, Bordeaux |
| ClinicalTrials.gov Identifier: | NCT00808730 History of Changes |
| Other Study ID Numbers: | CHUBX 2008/29 |
| Study First Received: | December 15, 2008 |
| Last Updated: | February 15, 2010 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by University Hospital, Bordeaux:
|
Asthma, airway remodelling, smooth muscle, mitochondria |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013